X. Chu

发表

Membrane transporters in drug development

M. Niemi, Y. Sugiyama, K. Giacomini, 2010, Nature Reviews Drug Discovery.

Comparison of Immortalized Fa2N-4 Cells and Human Hepatocytes as in Vitro Models for Cytochrome P450 Induction

X. Chu, R. Evers, N. Hariparsad, 2008, Drug Metabolism and Disposition.

Variability in P-Glycoprotein Inhibitory Potency (IC50) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria

M. Jamei, X. Chu, K. Hillgren, 2013, Drug Metabolism and Disposition.

Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study

W. Humphreys, X. Chu, Caroline A. Lee, 2018, Drug Metabolism and Disposition.

Identification of potential pharmacological and toxicological targets differentiating structural analogs by a combination of transcriptional profiling and promoter analysis in LS-180 and Caco-2 adenocarcinoma cell lines

Yudong D. He, R. Ulrich, C. Roberts, 2006, Pharmacogenetics and genomics.

Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats.

Y. Sugiyama, X. Chu, Y. Kato, 1997, Cancer research.

Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats.

Y. Sugiyama, X. Chu, Y. Kato, 1999, Drug metabolism and disposition: the biological fate of chemicals.

Acute and Chronic Effects of Rifampin on Letermovir Suggest Transporter Inhibition and Induction Contribute to Letermovir Pharmacokinetics

Michael E. Lassman, X. Chu, J. McCrea, 2021, Clinical pharmacology and therapeutics.

A Comparison of Total and Plasma Membrane Abundance of Transporters in Suspended, Plated, Sandwich-Cultured Human Hepatocytes Versus Human Liver Tissue Using Quantitative Targeted Proteomics and Cell Surface Biotinylation

S. Heyward, W. Humphreys, X. Chu, 2019, Drug Metabolism and Disposition.

Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug Interactions

K. Maeda, H. Kusuhara, Y. Sugiyama, 2022, Clinical pharmacology and therapeutics.

Physiologically‐based pharmacokinetic model‐based translation of OATP1B‐mediated drug–drug interactions from coproporphyrin I to probe drugs

K. Maeda, H. Kusuhara, X. Chu, 2022, Clinical and translational science.

A Microdose Cocktail to Evaluate Drug Interactions in Patients with Renal Impairment

Michael E. Lassman, D. Tweedie, X. Chu, 2020, Clinical pharmacology and therapeutics.

Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches

Yuichi Sugiyama, Aleksandra Galetin, Jan Snoeys, 2018, Clinical pharmacology and therapeutics.

Ontogeny of Hepatic Drug Transporters as Quantified by LC‐MS/MS Proteomics

X. Chu, R. Evers, A. Gaedigk, 2016, Clinical pharmacology and therapeutics.

Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug‐Drug Interaction Evaluation: Perspectives From the International Transporter Consortium

Yuichi Sugiyama, Hong Shen, Aleksandra Galetin, 2018, Clinical pharmacology and therapeutics.

Dabigatran Etexilate and Digoxin: Comparison as Clinical Probe Substrates for Evaluation of P‐gp Inhibition

D. Tweedie, X. Chu, Lei Zhang, 2018, Clinical pharmacology and therapeutics.

Role of transporters in the disposition of a novel β-lactamase inhibitor: relebactam (MK-7655).

X. Chu, K. Cox, Meihong Lin, 2019, The Journal of antimicrobial chemotherapy.

Function and expression of multidrug resistance-associated protein family in human colon adenocarcinoma cells (Caco-2).

Y. Sugiyama, X. Chu, I. Tamai, 2000, The Journal of pharmacology and experimental therapeutics.

Evaluation of hepatic uptake of OATP1B substrates by short term-cultured plated human hepatocytes: Comparison with isolated suspended hepatocytes.

H. Kusuhara, Y. Sugiyama, X. Chu, 2020, Journal of pharmaceutical sciences.

DMD057976 1301..1313

X. Chu, R. Evers, M. Mezler, 2014 .

Intestinal P‐gp and Putative Hepatic OATP1B Induction: International Transporter Consortium Perspective on Drug Development Implications

Y. Sugiyama, K. Brouwer, X. Chu, 2020, Clinical pharmacology and therapeutics.

An investigation of crosstalk between Wnt/β-catenin and transforming growth factor-β signaling in androgenetic alopecia

X. Chu, Zhidan Wu, Z. Bi, 2016, Medicine.

The metabolism and disposition of a potent inhibitor of hepatitis C virus NS3/4A protease

X. Chu, R. Evers, S. Harper, 2010, Xenobiotica; the fate of foreign compounds in biological systems.

Role of the Murine Organic Anion-Transporting Polypeptide 1b2 (Oatp1b2) in Drug Disposition and Hepatotoxicity

X. Chu, R. Evers, 2008, Molecular Pharmacology.

KEAP1/NRF2 signaling pathway mutations in cervical cancer.

X. Chu, X. Yang, Zaozao Zheng, 2018, European review for medical and pharmacological sciences.

[Pharmacokinetics and disposition of vinpocetine in rats].

X. Chu, J. Yao, C. Su, 1994, Yao xue xue bao = Acta pharmaceutica Sinica.

Transport of Ethinylestradiol Glucuronide and Ethinylestradiol Sulfate by the Multidrug Resistance Proteins MRP1, MRP2, and MRP3

X. Chu, R. Evers, B. Sarkadi, 2004, Journal of Pharmacology and Experimental Therapeutics.

Cell-to-Medium Concentration Ratio Overshoot in the Uptake of Statins by Human Hepatocytes in Suspension, but Not in Monolayer: Kinetic Analysis Suggesting a Partial Loss of Functional OATP1Bs

K. Maeda, H. Kusuhara, Y. Sugiyama, 2020, The AAPS Journal.

New and Emerging Research on Solute Carrier and ATP Binding Cassette Transporters in Drug Discovery and Development: Outlook From the International Transporter Consortium

Megan L. Koleske, Miles A. Miller, K. Giacomini, 2022, Clinical pharmacology and therapeutics.

Clinical Relevance of Hepatic and Renal P‐gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective

Y. Sugiyama, K. Brouwer, X. Chu, 2022, Clinical pharmacology and therapeutics.

Clinical Implications of Altered Drug Transporter Abundance/Function and PBPK Modeling in Specific Populations: An ITC Perspective

X. Chu, A. Galetin, M. Varma, 2022, Clinical pharmacology and therapeutics.

Polyethlyene Glycol 200 can Protect Rats against Drug-Induced Kidney Toxicity through Inhibition of the Renal Organic Anion Transporter 3.

X. Chu, K. Cox, Yi-Zhong Gu, 2019, Toxicological sciences : an official journal of the Society of Toxicology.

Intracellular Drug Concentrations and Transporters: Measurement, Modeling, and Implications for the Liver

Y. Sugiyama, K. Brouwer, X. Chu, 2013, Clinical pharmacology and therapeutics.

Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment.

X. Chu, Wen-en Zhao, Hong M Liu, 2016, Current topics in medicinal chemistry.

Transport of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin by Human Organic Anion Transporter 3, Organic Anion Transporting Polypeptide 4C1, and Multidrug Resistance P-glycoprotein

Shiyao Xu, Arthur J Bergman, X. Chu, 2007, Journal of Pharmacology and Experimental Therapeutics.

Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats.

Y. Sugiyama, X. Chu, Y. Kato, 1997, The Journal of pharmacology and experimental therapeutics.

The Complexities of Interpreting Reversible Elevated Serum Creatinine Levels in Drug Development: Does a Correlation with Inhibition of Renal Transporters Exist?

X. Chu, R. Evers, K. Bleasby, 2016, Drug Metabolism and Disposition.

Correlation between epithelial cell permeability of cephalexin and expression of intestinal oligopeptide transporter.

G. Amidon, X. Chu, K. Higaki, 2001, Journal of Pharmacology and Experimental Therapeutics.

PBPK models for evaluating membrane transporter mediated DDIs: Current capabilities, case studies, future opportunities and recommendations.

Yuichi Sugiyama, Ming Zheng, Jan Snoeys, 2019, Clinical pharmacology and therapeutics.

Application of Receiver Operating Characteristic Analysis to Refine the Prediction of Potential Digoxin Drug Interactions

Sophie P. Chung, Shibing Deng, M. Jamei, 2013, Drug Metabolism and Disposition.

DMD050542 1367..1374

Sophie P. Chung, Shibing Deng, M. Jamei, 2013 .

Interindividual and Regional Variability in Drug Transporter Abundance at the Human Blood–Brain Barrier Measured by Quantitative Targeted Proteomics

Bhagwat Prasad, Yurong Lai, Jashvant D Unadkat, 2019, Clinical pharmacology and therapeutics.

Drug–Drug Interaction Studies: Regulatory Guidance and An Industry Perspective

Donghui Cui, Thomayant Prueksaritanont, X. Chu, 2013, The AAPS Journal.

Identification of pregnane-X receptor target genes and coactivator and corepressor binding to promoter elements in human hepatocytes

X. Chu, R. Evers, N. Hariparsad, 2009, Nucleic acids research.

Estrogen receptor 1 mutations in 260 cervical cancer samples from Chinese patients

X. Chu, Xin-Min Yang, Liqun Wang, 2019, Oncology letters.

Interspecies Variability in Expression of Hepatobiliary Transporters across Human, Dog, Monkey, and Rat as Determined by Quantitative Proteomics

X. Chu, R. Evers, J. Unadkat, 2015, Drug Metabolism and Disposition.

Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance

Yan Zhang, Lei Zhang, K. Giacomini, 2018, Clinical pharmacology and therapeutics.

Species differences in drug transporters and implications for translating preclinical findings to humans

X. Chu, R. Evers, Xiaoyan Chu, 2013, Expert opinion on drug metabolism & toxicology.

Active efflux of CPT-11 and its metabolites in human KB-derived cell lines.

Y. Sugiyama, X. Chu, S. Akiyama, 1999, The Journal of pharmacology and experimental therapeutics.

Understanding the Transport Properties of Metabolites: Case Studies and Considerations for Drug Development

X. Chu, J. Polli, A. Galetin, 2014, Drug Metabolism and Disposition.

Rifampin's Acute Inhibitory and Chronic Inductive Drug Interactions: Experimental and Model‐Based Approaches to Drug–Drug Interaction Trial Design

C Gibson, X. Chu, R. Evers, 2011, Clinical pharmacology and therapeutics.

In Vitro Assessment of Transporter Mediated Perpetrator DDIs for Several Hepatitis C Virus Direct-Acting Antiviral Drugs and Prediction of DDIs with Statins Using Static Models

X. Chu, Meihong Lin, J. Yabut, 2022, The AAPS Journal.

Characterization of Mice Lacking the Multidrug Resistance Protein Mrp2 (Abcc2)

X. Chu, R. Evers, J. Yabut, 2006, Journal of Pharmacology and Experimental Therapeutics.

Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters.

Y. Sugiyama, X. Chu, Y. Kato, 1998, Cancer research.

ITC Commentary on Metformin Clinical Drug–Drug Interaction Study Design That Enables an Efficacy‐ and Safety‐Based Dose Adjustment Decision

K. Giacomini, X. Chu, Caroline A. Lee, 2018, Clinical pharmacology and therapeutics.

Evaluation Vitro In Inhibition of Major Drug Transporters : an Clinical Drug Interactions through Raltegravir Has a Low Propensity To Cause

X. Chu, M. Rizk, Elizabeth G. Rhee, 2014 .

Raltegravir Has a Low Propensity To Cause Clinical Drug Interactions through Inhibition of Major Drug Transporters: an In Vitro Evaluation

X. Chu, M. Rizk, Elizabeth G. Rhee, 2013, Antimicrobial Agents and Chemotherapy.

Characterization of Multidrug Resistance 1a/P-Glycoprotein Knockout Rats Generated by Zinc Finger Nucleases

Zuo Zhang, X. Chu, R. Evers, 2012, Molecular Pharmacology.

Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein

Y. Sugiyama, X. Chu, Y. Kato, 2009, Cancer Chemotherapy and Pharmacology.

Transporters affecting biochemical test results: Creatinine‐drug interactions

X. Chu, R. Evers, K. Bleasby, 2016, Clinical pharmacology and therapy.

Identification of Endogenous Biomarkers to Predict the Propensity of Drug Candidates to Cause Hepatic or Renal Transporter-Mediated Drug-Drug Interactions.

X. Chu, R. Evers, G. Chan, 2017, Journal of pharmaceutical sciences.

Evaluation of Cynomolgus Monkeys for the Identification of Endogenous Biomarkers for Hepatic Transporter Inhibition and as a Translatable Model to Predict Pharmacokinetic Interactions with Statins in Humans

X. Chu, R. Evers, A. Fernandis, 2015, Drug Metabolism and Disposition.

Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development

X. Chu, Xingrong Liu, L. Di, 2022, Acta pharmaceutica Sinica. B.

Coproporphyrin I as an Endogenous Biomarker to Detect Reduced OATP1B Activity and Shift in Elimination Route in Chronic Kidney Disease

X. Chu, A. Galetin, K. Ogungbenro, 2022, Clinical pharmacology and therapy.

Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.

Prajakti A Kothare, Thomayant Prueksaritanont, X. Chu, 2014, British journal of clinical pharmacology.

Positron Emission Tomography Imaging of [11C]Rosuvastatin Hepatic Concentrations and Hepatobiliary Transport in Humans in the Absence and Presence of Cyclosporin A

Mark Muzi, Yurong Lai, Laigao Chen, 2019, Clinical pharmacology and therapeutics.

Evaluation of Organic Anion Transporting Polypeptide 1B1 and 1B3 Humanized Mice as a Translational Model to Study the Pharmacokinetics of Statins

X. Chu, R. Evers, M. Mezler, 2014, Drug Metabolism and Disposition.

In Vitro Techniques to Study Transporter-Based DDI

X. Chu, R. Evers, K. Bleasby, 2010 .

Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers

X. Chu, P. Jumes, J. Butterton, 2019, Antimicrobial Agents and Chemotherapy.

Absorption, Metabolism, Distribution, and Excretion of Letermovir.

X. Chu, P. Kothare, J. McCrea, 2021, Current drug metabolism.

Determining P-glycoprotein-drug interactions: evaluation of reconstituted P-glycoprotein in a liposomal system and LLC-MDR1 polarized cell monolayers.

X. Chu, R. Evers, S. Wright, 2012, Journal of pharmacological and toxicological methods.

Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A

W. Zeng, R. Railkar, X. Chu, 2017, Clinical pharmacology and therapeutics.

Transporter Expression in Noncancerous and Cancerous Liver Tissue from Donors with Hepatocellular Carcinoma and Chronic Hepatitis C Infection Quantified by LC-MS/MS Proteomics

W. Humphreys, X. Chu, R. Evers, 2018, Drug Metabolism and Disposition.

Transporter Expression in Liver Tissue from Subjects with Alcoholic or Hepatitis C Cirrhosis Quantified by Targeted Quantitative Proteomics

Li Wang, Carol Collins, Cornelis E. C. A. Hop, 2016, Drug Metabolism and Disposition.

Prediction of Transporter-Mediated Rosuvastatin Hepatic Uptake Clearance and Drug Interaction in Humans Using Proteomics-Informed REF Approach

S. Heyward, W. Humphreys, X. Chu, 2020, Drug Metabolism and Disposition.

Metabolism and Renal Elimination of Gaboxadol in Humans: Role of UDP-Glucuronosyltransferases and Transporters

X. Chu, R. Evers, M. Braun, 2009, Pharmaceutical Research.

BILIARY EXCRETION MECHANISM OF IRINOTECAN CPT-1 1 AND ITS METABOLITES IN HUMANS AND RATS: INVOLVEMENT OF cMOAT and P-gp

Y. Sugiyama, X. Chu, Y. Kato, 1998 .

Role of MRP family proteins in the export of organic anion compounds from liver and intestine

Y. Sugiyama, X. Chu, Takao Shimizu, 1997 .

Interlaboratory Variability in the Madin–Darby Canine Kidney Cell Proteome

X. Chu, J. Wiśniewski, S. Neuhoff, 2023, Molecular Pharmaceutics.

Drug–Drug Interaction Studies: Regulatory Guidance and An Industry Perspective

X. Chu, J. Hochman, T. Prueksaritanont, 2013, The AAPS Journal.

In Vitro Assessment of Drug-Drug Interaction Potential of Boceprevir Associated with Drug Metabolizing Enzymes and Transporters

X. Chu, R. Evers, T. Prueksaritanont, 2013, Drug Metabolism and Disposition.

Identification of a Human Valacyclovirase

G. Amidon, X. Chu, Kyung-Dall Lee, 2003, Journal of Biological Chemistry.

Pharmacokinetic Interactions Between the HCV Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, or Darunavir in Healthy Participants

X. Chu, P. Jumes, J. Butterton, 2019 .

ITC Recommendations for Transporter Kinetic Parameter Estimation and Translational Modeling of Transport‐Mediated PK and DDIs in Humans

M Jamei, M. Jamei, X. Chu, 2013, Clinical pharmacology and therapeutics.

Selection of an Optimal In Vitro Model to Assess P-gp Inhibition: Comparison of Vesicular and Bidirectional Transcellular Transport Inhibition Assays

Lucinda R. Hittle, X. Chu, J. Yabut, 2022, Drug Metabolism And Disposition.

Generation and Characterization of a Breast Cancer Resistance Protein Humanized Mouse Model

X. Chu, M. Mezler, O. Langer, 2016, Molecular Pharmacology.

Comparison of Immortalized Fa 2 N4 Cells and Human Hepatocytes as in Vitro Models for Cytochrome P 450 Induction

X. Chu, R. Evers, N. Hariparsad, 2008 .

Understanding the Transport Properties of Metabolites: Case Studies and Considerations for Drug Development

X. Chu, J. Polli, A. Galetin, 2014, Drug Metabolism and Disposition.

Characterization of Multidrug Resistance 1a/P-Glycoprotein Knockout Rats Generated by Zinc Finger Nucleases

Zuo Zhang, X. Chu, R. Evers, 2012, Molecular Pharmacology.